Acute Lymphoblastic Leukemia
Conditions
Keywords
Acute lymphoblastic leukemia, Ponte-di-Legno consortium, Second cancer, Survival
Brief summary
Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.
Detailed description
To explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical, biological, and cytogenetic characteristics (myeloid neoplasias only) as well as outcome. Furthermore, we will register the clinical, biological, and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given.
Interventions
None listed
Sponsors
Nordic Society for Pediatric Hematology and Oncology
European Organisation for Research and Treatment of Cancer - EORTC
Dana-Farber Cancer Institute
ALL-BFM Study Group
Dutch Childhood Oncology Group
St. Jude Children's Research Hospital
United Kingdom Children's Cancer Study Group
Rigshospitalet, Denmark
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 20 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with childhood acute lymphoblastic leukemia * Diagnosis of second cancer before December 31st 2007
Exclusion criteria
* Uncertainty if the second cancer has emerged from the same original leukemic clone
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pattern of SMN subtypes | At 20 years from diagnosis | Pattern of the main groups of SMN and their clinical charactiristics |
| Overall survival by subtype | At 10 years from diagnosis of SMN | Overall survival by the main SMN subtypes (myeloid malignancies, brain tumors, lymphomas, sarcomas, carcinomas, others) |
| Risk factors for development of SMN | At 20 years from ALL diagnosis | Identification of risk factors linked to the interval to SMN, the subtype of SMN, and the survival after. These risk factors are clinical characteristics of ALL or the anti-ALL therapy administered |
Countries
Denmark
Outcome results
None listed